click enter text
full postview lower qualiti ep beat feed
report financi result wednesday open
revenu lighter vs us consensu ep beat perform
certain key brand fell short feed bear case guidanc may
high
guidanc rais non-gaap ep driver lower tax
favor income/expens press variou way
prior guidanc manag remain steadfast
chang model rel modest revenu
gener drift lower ep depend year pt
bodi report full analysi
inform us/eu stock cover see
recent report septemb issu monthli
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
wednesday market open
report result lower revenu beat ep vs consensu us
saw share price close much one point day under-perform
overal impress despit beat rais quarter share came pressur reflect
weaker perform variou key brand within diabet therapeut area sum
price eros across lli book busi us w/w year year continu
concern street prior guidanc whether achiev press
numer occas us analyst manag unwav optim
committ believ target achiev come combin good
volum growth off-set modest price declin flattish oper spend opinion guidanc may
fact achiev soon know worth appreci consist deliver
financi result last mani year compani sanofi novonordisk blow
wrong guidanc diabet franchis perform deliv also didnt help
wednesday compani announc retir compani long-tim head diabet
high leverag area total compani sale competit threat continu
multipli stock perspect share struggl lead declin valuat
rel earlier year price-to-earnings multipl still screen higher end versu peer
investor base seem destin maintain wait see approach exampl novonordisk oral
semaglutid like take least coupl quarter worth launch experi investor feel
better assess durabl trulic growth mean stock may continu stay limbo
especi pipelin light near-term catalyst wit amount time spent talk
phase pipelin industri statist show roughli early-stag compound ultim fail
 past often clearli said look small bolt-on wednesday confer
call seem littl vagu term choic languag ask appetit deal
term sale ep exhibit
revenu slightli lower vs consensu
non-gaap ep higher vs consensu lower anticip tax rate
contribut boost ep
trulic lower consensu lower realiz price
compound increas fund medicar coverag gap inventori burn taltz
lower vs consensu
term guidanc exhibit
revenu maintain
page
non-gaap ep rais vs
tax rate lower vs prior
reiter oper margin least
pipelin noth materi new compani host alzheim diseas shot goal
earli and/or meaning data far away
revenu decreas ep increas
revenu estim chang decreas ep estim
rang depend year oper margin remain slightli
guidanc also consensu model
ep compound-annual-growth-rate ep compound-annual-growth-rate decreas still well peer averag
price target decreas slightli vs prior repres lower vs
new slightli higher ep estim multipl still peer group averag
reflect compani better compar lt ep growth rate
enriqu conterno head diabet retir compani replac intern candid
launch trulic jardianc
us price declin expect higher rebat increas donut hole fund
saw impact less
remain commit guidanc goal previous given
 price assumpt expect singl digit price eros like saw
previous expect low sd price eros still feel pretti comfort
 opportun cost save go forward said comfort current absolut
level infrastructur build-out suggest flattish oper spend
 expect first gave guidanc term competit threat etc say
gave middl admit competit environ evolv variou way
page
gave guidanc felt street low vs intern forecast meant show
confid aggreg futur growth made good progress toward achiev
goal
 plan aggress want add current pipelin bd ta
phase develop whether find valu howev alway challeng say
doesnt come particular financi framework apart abl creat valu oncolog
remain focu area wolf comment usual make clear focu bolt-on
 street quit oper margin guidanc street get
wrong respect revenu target still comfort cant point
specif area within consensu model feel good current level invest believ top-
line growth biggest contributor oper expens growth modest gener reiter
comfort previously-given target
 investor confid guidanc given weak variou line-item seen
doesnt enriqu departur portend problem diabet also given weak stock
big share buyback ceo dave rick talk great time
expect headwind like donut hole step-up ciali loe diabet
reiter confid outlook mean everi singl quarter hit everi item right
taken togeth outlook remain bright enriqu retir enriqu answer
question reiter bright futur diabet includ trulic jardianc tirzepatid
say couldnt excit futur diabet compani buyback say
opportunist want retain flexibl busi develop
 expect term us healthcar reform say wish specif inform
offer hard see legisl happen time still
trulic us price declin y/i exclud one-off expect level declin
subsequ quarter
 approv oral sema see aggress price environ
manag class remind trulic unpreced coverag expect good
coverag next year earli talk impact oral sema
 stock despit beat rais part reflect uncertainti target
competit threat diabet give detail manag care contract look
diabet term net live gained/lost price concess made trulic
jardianc said good trulic access reiter mode y/i price declin
trulic us
 jardianc heart failur trial view commerci opportun see
signific opportun compani blockbust potenti believ walk test fileabl
page
data outcom data come end hfpef data earli also read jardianc
chronic kidney diseas
 trulic gain new traction trulic disproportion growth lower price
channel recent look forward see balanc growth across payer segment
regard endo still see good class trulic growth pcp segment
 trulic sold part channel say
 taltz price outlook coverag look access continu
challeng expect perhap increment better access
 taltz price concess maintain access say littl bit differ
trulic rx reimburs primari payer therefor happi
pay rebat gain access transit free product reimburs product
prior period adjust rel assum previous part wont repeat go forward
 on-going solanezumab trial dose higher provid updat remind
asymptomat patient plaqu posit data
 past coupl year seem begin believ monotherapi a-beta
treatment would deliv result focu therefor combin light
news compani latest think feel news support amyloid
hypothesi still think plaqu remov could work thu focu yesterday news
reason bit optimist inde think combin therapi import variou
asset combin remind bace mab combo didnt work mention on-going work
area tau
verzenio new os result effect re-launch drug
 emgal outlook becam leader nrx access us thu far
still earli day larg target popul net tremend opportun ahead
pegilodecakin armo lung renal trial still track despit pancreat cancer failur
spent time talk asset note initi compani ever
past slide
page
exhibit show compani report actual result vs estim consensu
exhibit result vs wr estim consensu
exhibit summar lli financi guidanc vs estim
page
exhibit guidanc vs wr estim old new exclud elanco
exhibit captur chang forecast
exhibit chang wr model
page
oldnewprior wolf estimatewolf bgross marginapprox bother meffect tax rateapprox oper incom approx pharma guidancewr estimatesp revenu margin exp margin incom
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement incom loss cont op dilut share growth outstand
page
product revenu emgal galcanezumab anti-cgrp growth share tradjenta basaglar biosimilar share jardianc trulic women endocrinolog growth diabet alimta cyramza gastric lartruvo olaratumab verzenio abemaciclib erbitux total taltz ixekizumab olumi baricitinib jak total total earli stage factor- total
exhibit wr eli lilli balanc sheet cash flow statement
page
summari statement incom reconcil incom tax cash provid oper tax chang oper asset defer compens impair net in-process technolog net cash provid sale in-process product paid acq/loan cash provid use invest stock capit chang short term issuanc long term repay long-term cash provid use financ exchang rate cash increas decreas end balanc sheet cash equival short term properti plant goodwil current term non-curr paid-in comprehens treasuri stock sharehold liabil sharehold
